INmune Bio (INMB) Set to Announce Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is set to announce its earnings results after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

INmune Bio Trading Up 4.4 %

Shares of INmune Bio stock opened at $5.22 on Friday. The stock has a 50-day moving average price of $5.74 and a 200 day moving average price of $7.98. The company has a market cap of $103.26 million, a P/E ratio of -2.72 and a beta of 1.85. INmune Bio has a 1 year low of $4.78 and a 1 year high of $14.74.

Insider Transactions at INmune Bio

In other news, CEO Raymond Joseph Tesi purchased 15,380 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the purchase, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at approximately $9,915,196.28. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Raymond Joseph Tesi purchased 15,380 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the purchase, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at approximately $9,915,196.28. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO David J. Moss purchased 10,000 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were purchased at an average cost of $5.29 per share, with a total value of $52,900.00. Following the completion of the purchase, the chief financial officer now directly owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 33,070 shares of company stock valued at $200,087 in the last three months. Corporate insiders own 35.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Raymond James assumed coverage on INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective for the company. Scotiabank assumed coverage on INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective for the company. Finally, Alliance Global Partners started coverage on INmune Bio in a research note on Monday. They issued a “buy” rating and a $20.00 price objective for the company.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.